237 related articles for article (PubMed ID: 31689995)
1. Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.
Kaka N; Hafazalla K; Samawi H; Simpkin A; Perry J; Sahgal A; Das S
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31689995
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in patients with newly diagnosed glioblastoma-A systematic meta-analysis of randomized clinical trials.
Scherm A; Ippen FM; Hau P; Baurecht H; Wick W; Gempt J; Knüttel H; Leitzmann MF; Seliger C
Int J Cancer; 2023 Jun; 152(11):2373-2382. PubMed ID: 36647335
[TBL] [Abstract][Full Text] [Related]
4. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Wang Y; Xing D; Zhao M; Wang J; Yang Y
PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
[TBL] [Abstract][Full Text] [Related]
5. Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials.
Lan XY; Li D; Li S; Zhong LZ; Zhao H; Xi YL; Sun ZW
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3522-3533. PubMed ID: 35647833
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.
Fu P; He YS; Huang Q; Ding T; Cen YC; Zhao HY; Wei X
Mol Clin Oncol; 2016 May; 4(5):833-838. PubMed ID: 27123291
[TBL] [Abstract][Full Text] [Related]
8. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
9. Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
Seliger C; Genbrugge E; Gorlia T; Chinot O; Stupp R; Nabors B; Weller M; Hau P;
Int J Cancer; 2020 Feb; 146(3):803-809. PubMed ID: 30980539
[TBL] [Abstract][Full Text] [Related]
10. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis.
Ren X; Ai D; Li T; Xia L; Sun L
Front Neurol; 2020; 11():603947. PubMed ID: 33551965
[No Abstract] [Full Text] [Related]
12. The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis.
Liao KL; Huang S; Wu YP
Onco Targets Ther; 2018; 11():3513-3520. PubMed ID: 29950856
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
Han K; Ren M; Wick W; Abrey L; Das A; Jin J; Reardon DA
Neuro Oncol; 2014 May; 16(5):696-706. PubMed ID: 24335699
[TBL] [Abstract][Full Text] [Related]
19. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.
Sun MZ; Oh T; Ivan ME; Clark AJ; Safaee M; Sayegh ET; Kaur G; Parsa AT; Bloch O
J Neurosurg; 2015 May; 122(5):1144-50. PubMed ID: 25768833
[TBL] [Abstract][Full Text] [Related]
20. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
